In terms of lung cancer, a recent study reported that patients with non-small-cell lung carcinomas (NSCLCs) exhibited MARS overexpression in tumor cells, and that poor clinical outcomes were closely associated with the MARS staining intensity and proportion [9]. This evidence concerns the gene MARS1 and non-small cell lung carcinoma.